1. Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET
- Author
-
Farolfi, Andrea, Ilhan, Harun, Gafita, Andrei, Calais, Jeremie, Barbato, Francesco, Weber, Manuel, Afshar-Oromieh, Ali, Spohn, Fabian, Wetter, Axel, Rischpler, Christoph, Hadaschik, Boris, Pianori, Davide, Fanti, Stefano, Haberkorn, Uwe, Eiber, Matthias, Herrmann, Ken, and Fendler, Wolfgang Peter
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Urologic Diseases ,Cancer ,Biomedical Imaging ,Aging ,Prostate Cancer ,Aetiology ,2.1 Biological and endogenous factors ,Antigens ,Surface ,Glutamate Carboxypeptidase II ,Humans ,Image Processing ,Computer-Assisted ,Lymph Node Excision ,Male ,Positron-Emission Tomography ,Prostatic Neoplasms ,Salvage Therapy ,Treatment Failure ,PET ,prostate cancer ,PSA persistence ,PSMA ,salvage lymph node dissection ,Nuclear Medicine & Medical Imaging ,Clinical sciences - Abstract
The aim of this study was to analyze patterns of persistent versus recurrent or new PET lesions in a selected patient cohort with prostate-specific antigen (PSA) persistence after salvage lymph node dissection (SLND) and pre-procedure and post-procedure prostate-specific membrane antigen (PSMA) ligand PET. Methods: Sixteen patients were included in this multicenter study. The inclusion criteria were PSMA PET performed for biochemical recurrence before SLND (pre-SLND PET) and repeat PSMA PET performed for a persistently elevated PSA level (≥0.1 ng/mL) at least 6 wk after SLND (post-SLND PET). Image analysis was performed by 3 independent nuclear medicine physicians applying the molecular imaging TNM system PROMISE. Lesions were confirmed by histopathology, presence on correlative CT/MRI/bone scanning, or PSA response after focal therapy. Results: Post-SLND PET identified prostate cancer lesions in 88% (14/16) of patients with PSA persistence after SLND. Median PSA was 1.2 ng/mL (interquartile range, 0.6-2.8 ng/mL). Disease was confined to the pelvis in 56% of patients (9/16), and most of these men had common iliac (6/16, 38%) and internal iliac lymph node metastases (6/16, 38%). Extrapelvic disease was detected in 31% of patients (5/16). In pre- and post-SLND PET comparison, 10 of 16 had at least one lesion already detected at baseline (63% PET persistence), 4 of 16 had new lesions only (25% PET recurrence), and 2 had no disease on post-SLND PET. All validated regions (11 regions in 9 patients) were true-positive. Nine of 14 (64%) patients underwent repeat local therapies after SLND (7/14 radiotherapy, 2/14 surgery). Conclusion: SLND of pelvic nodal metastases was often not complete according to PSMA PET. About two thirds of patients had PET-positive nodal disease after SLND already seen on pre-SLND PSMA PET. Notably, about one quarter of patients had new lesions, not detected by presurgical PSMA PET.
- Published
- 2020